QUESTION: What do ZostaVax®, Kineret® and Macugen® have in common…
ANSWER: They are all FDA approved first-in-class commercialized products originating from University of Colorado intellectual property.
Want to learn more about these products and the rich product pipeline portfolio at the University of Colorado? Then take a listen to this podcast featuring David Allen, Ph.D., Associate Vice President, CU Technology Transfer Office speaking at the Holland & Hart Bioentrepreneur Club and observe the year-end performance metrics through July 2007 (here).
ZostaVax® is a vaccine developed by Merck & Co. (NYSE: MRK) which has been shown to reduce the incidence of Shingles (herpes zoster) by over 51% in a pivotal phase III study of 38,000 adults aged 60 and older who received the vaccine.
Macugen® is for the treatment of neovascular (wet) age-related macular degeneration. It was developed by EyeTech Pharmaceuticals who was recently acquired by OSI Pharmaceuticals (NASDAQ: OSIP) and licensed to Pfizer (NYSE: PFE) for late stage development and marketing.
Kineret® developed by Amgen (NASDAQ: AMGN) for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs.